HomeCompareSEEL vs BTI

SEEL vs BTI: Dividend Comparison 2026

SEEL yields 540.54% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SEEL wins by $112786.19M in total portfolio value
10 years
SEEL
SEEL
● Live price
540.54%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112786.22M
Annual income
$82,692,515,806.61
Full SEEL calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — SEEL vs BTI

📍 SEEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEELBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEEL + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEEL pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEEL
Annual income on $10K today (after 15% tax)
$45,945.95/yr
After 10yr DRIP, annual income (after tax)
$70,288,638,435.62/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, SEEL beats the other by $70,288,636,053.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEEL + BTI for your $10,000?

SEEL: 50%BTI: 50%
100% BTI50/50100% SEEL
Portfolio after 10yr
$56393.13M
Annual income
$41,346,259,304.45/yr
Blended yield
73.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SEEL
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-156.6
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEEL buys
0
BTI buys
0
No recent congressional trades found for SEEL or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEELBTI
Forward yield540.54%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$112786.22M$37.8K
Annual income after 10y$82,692,515,806.61$2,802.29
Total dividends collected$110217.05M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: SEEL vs BTI ($10,000, DRIP)

YearSEEL PortfolioSEEL Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$64,754$54,054.05$11,301$601.08+$53.5KSEEL
2$396,410$327,123.28$12,799$706.58+$383.6KSEEL
3$2,295,726$1,871,567.31$14,527$832.38+$2.28MSEEL
4$12,586,137$10,129,710.14$16,527$982.75+$12.57MSEEL
5$65,369,349$51,902,182.37$18,846$1,162.95+$65.35MSEEL
6$321,877,325$251,932,121.38$21,545$1,379.49+$321.86MSEEL
7$1,503,762,535$1,159,353,797.14$24,694$1,640.41+$1503.74MSEEL
8$6,671,013,644$5,061,987,731.83$28,378$1,955.69+$6670.99MSEEL
9$28,124,961,234$20,986,976,635.20$32,702$2,337.79+$28124.93MSEEL
10$112,786,224,327$82,692,515,806.61$37,794$2,802.29+$112786.19MSEEL

SEEL vs BTI: Complete Analysis 2026

SEELStock

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full SEEL Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this SEEL vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEEL vs SCHDSEEL vs JEPISEEL vs OSEEL vs KOSEEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.